Oral insulin delivery by means of solid lipid nanoparticles

International Journal of Nanomedicine

Volumn 2, Issue 4, 2007, Pages 743-749

  Sarmento, Bruno ^a   Martins, Susana ^a   Ferreira, Domingos ^a   Souto, Eliana B ^a,b  

^a UNIVERSITY OF PORTO   (Portugal)

^b UNIVERSIDADE FERNANDO PESSOA   (Portugal)

Author keywords

Cetyl palmitate; Hypoglycemic effect; Insulin; Oral administration; Solid lipid nanoparticles

Indexed keywords

DRUG CARRIER; GLUCOSE; INSULIN; INSULIN ZINC SUSPENSION; SOLID LIPID NANOPARTICLE; SOLVENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COLLOID; CONTROLLED STUDY; DIABETES MELLITUS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG EFFECT; EMULSION; EVAPORATION; GLUCOSE BLOOD LEVEL; MALE; NONHUMAN; PARTICLE SIZE; RAT; ZETA POTENTIAL;

ADMINISTRATION, ORAL; ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS; DRUG CARRIERS; INSULIN; MALE; NANOPARTICLES; PALMITATES; RATS; RATS, WISTAR; TREATMENT OUTCOME;

RATTUS;

EID: 41849134910     PISSN: 11769114     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Asada H, Douen T, Waki M, et al. 1995. Absorption characteristics of chemically modified-insulin derivates without fatty acids in the small and large intestine. J Pharm Sci, 94:682-7.
2. Beals JM, Kovach P. 1997. Insulin. In: Crommelin DJA, Sindelar RD. Pharmaceutical biotechnology. Netherlands: Harwood Academic Publishers. p. 229-39.
3. Bendayan M, Ziv E, Gingras D, et al. 1994. Biochemical and morphocytochemical evidence for the intestinal absorption of insulin in control and diabetic rats. Comparison between the effectiveness of duodenal and colon mucosa. Diabetologia, 37:119-26.
4. Brange J. 1997. Galenics of insulin: the physico-chemical and pharmaceutical aspects of insulin and insulin preparations. Springer-Verlag.
5. Carino GP, Mathiowitz E. 1999. Oral insulin delivery. Adv Drug Deliv Rev, 35:249-57.
6. Celebi N, Turkyilmaz A, Gonul B, et al. 2002. Effects of epidermal growth factor microemulsion formulation on the healing of stress-induced gastric ulcer in rats. J Control Release, 83:197-210.
7. Clark MA, Jepson MA, Hirst BH. 2001. Exploiting M cells for drug and vaccine delivery. Adv Drug Deliv Rev, 50:81-106.
8. Cui F, Shi K, Zhang L, et al. 2006. Biodegradable nanoparticles loaded with insulin-phospholipid complex for oral delivery: Preparation, in vitro characterization and in vivo evaluation. J Control Release, 114:242-50.
9. Damge C, Vrancks H, Balschmidt P, et al. 1997. Poly(alkyl cyanoacrylate) nanospheres for oral administration of insulin. J Pharm Sci, 86:1407-500.
10. des Rieux A, Fievez V, Garinot M, et al. 2006. Nanoparticles as potential oral delivery systems of proteins and vaccines: A mechanistic approach. J Control Release, 116:1-27.
11. Eldridge JH, Hammond CJ, Meulbroek JA, et al. 1990. Controlled vaccine release in the gut-associated lymphoid tissues. I. Orally administered biodegradable microspheres target the peyer's patches. J Control Release, 11:205-14.
12. Garcia-Fuentes M, Prego C, Torres D, et al. 2005. A comparative study of the potential of solid triglyceride nanostructures coated with chitosan or poly(ethylene glycol) as carriers for oral calcitonin delivery. Eur J Pharm Sci, 25:123-33.
13. Garcia-Fuentes M, Torres D, Alonso MJ. 2003. Design of lipid nanoparticles for the oral delivery of hydrophilic macromolecules. Colloid Surface B, 27:159-68.
14. Garcia-Fuentes M, Torres D, Alonso MJ. 2005. New surface-modified lipid nanoparticles as delivery vehicles for salmon calcitonin. Int J Pharm, 296:122-32.
15. Hoffman A, Ziv E. 1997. Pharmacokinetic considerations of new insulin formulations and routes of administration. Clin Pharmacokinet, 33:285-301.
16. Hu FQ, Yuan H, Zhang HH, et al. 2002. Preparation of solid lipid nanopartictes with clobetasol propionate by a novel solvent diffusion method in aqueous system and physicochemical characterization. Int J Pharm, 239:121-8.
17. Hussain N, Jaitley V, Florence AT. 2001. Recent advances in the understanding of uptake ofmicroparticulates across the gastrointestinal lymphatics. Adv Drug Deliv Rev, 50:107-42.
18. Jung T, Kamm W, Breitenbach A, et al. 2000. Biodegradable nanoparticles for oral delivery of peptides: is there a role for polymers to affect mucosal uptake? Eur J Pharm Biopharm, 50:147-60.
19. Kim B, Peppas NA. 2003. In vitro release behavior and stability of insulin in complexation hydrogels as oral drug delivery carriers. Int J Pharm, 266:29-37.
20. Kim SJ, Choi HK, Suh SP, et al. 2002. Pharmacokinetic and pharmacodynamic evaluation of cyclosporine an o/w-emulsion and microsphere formulations in rabbits. Eur J Pharm Sci, 15:497-502.
21. Kisel MA, Kulik LN, Tsybovsky IS, et al. 2001. Liposomes with phosphatidylethanol as a carrier for oral delivery of insulin: studies in the rat. Int J Pharm, 216:105-14.
22. Komplella UB, Lee VHL. 2001. Delivery systems for penetration enhancement of peptide and protein drugs: design considerations. Adv Drug Deliv Rev, 46:211-45.
23. Lin YH, Mi FL, Chen CT, et al. 2007. Preparation and characterization of nanoparticles shelled with chitosan for oral insulin delivery. Biomacromolecules, 8: 146-52.
24. Lowe PL, Temple CS. 1994. Calcitonin and insulin in isobutilcyanoacrylate nanocapsules: Protection against proteases and effect on intestinal absorption J Pharm Pharmacol, 46:547-52.
25. Lukowski G, Kasbohm J, Pflegel P, et al. 2000. Crystallographic investigation of cetylpalmitate solid lipid nanoparticles. International Journal of Pharmaceutics, 196:201-5.
26. Muller RH, Lippacher A, Gohala S. 2000. Solid lipid nanoparticles (SLN) as carrier system for the controlled release of drugs. In: Wise DL. Handbook of Pharmaceutical controlled release technology. Marcel Dekker. p 377-91.
27. Muller RH, Lucks JS. 1996. Azneistoffträger aus festen Lipidteilchen feste Lipid Nanosphären (SLN). European Patent 0605497: Germany.
28. Muller RH, Maaen S, Weyhers H, et al. 1996. Cytotoxicity of magnetite-loaded polylactide, polylactide/glycolide particles and solid lipid nanoparticles. Int J Pharm, 138:85-94.
29. Muller RH, Ruhl D, Runge S. 1996. Biodegradation of solid lipid nanoparticles as a function of lipase incubation time. Int J Pharm, 144:115-21.
30. Muller RH, Ruhl D, Runge S, et al. 1997. Cytotoxicity of Solid lipid nano-particles as a function of the lipid matrix and the surfactant. Pharm Res, 14:458-62.
31. Muller RH, Runge S, Ravelli V, et al. 2006. Oral bioavailability of cyclosporine: solid lipid nanoparticles (SLN) versus drug nanocrystals. Int J Pharm, 317:82-9.
32. Olbrich C, Muller RH. 1999. Enzymatic degradation of SLN - effect of surfactant and surfactant mixtures. Int J Pharm, 180:31-9.
33. Owens DR. 2002. New horizons - Alternative routes for insulin therapy. Nat Rev Drug Discov, 1:529-40.
34. Pan Y, Li YJ, Zhao HY, et al. 2002. Bioadhesive polysaccharide in protein delivery system: chitosan nanoparticles improve the intestinal absorption of insulin in vivo. Int J Pharm, 249:139-47.
35. Rawat M, Singh D, Saraf S, et al. 2006. Nanocarriers: Promising Vehicle for Bioactive Drugs. Biol Pharm Bull, 29:1790-8.
36. Saffran M, Field JB, Pena J, et al. 1991. Oral insulin in diabetic dogs. J Endocrinol, 131:267-78.
37. Sarmento B, Ribeiro A, Veiga F, et al. 2006. Development and validation of a rapid reversed-phase HPLC method for the determination of insulin from nanoparticulate systems. Biomed Chromatogr, 20:898-903.
38. Souto EB. 2005. SLN and NLC for topical delivery of antifungals. Ph.D Thesis. Freie Universitat Berlin, Berlin.
39. Souto EB, Müller RH. 2007. Lipid nanoparticles (SLN and NLC) for drug delivery. In: Domb AJ, Tabata Y, Kumar MNVR, et al. Nanoparticles for pharmaceutical applications. American Scientific Publishers. p. 103-22.
40. Tobio M, Gref R, Sanchez A, et al. 1998. Stealth PLA-PEG Nanoparticles as Protein Carriers for Nasal Administration. Pharm Res, 15:270-5.
41. Tobio M, Sanchez A, Vila A, et al. 2000. The role of PEG on the stability in digestive fluids and in vivo fate of PEG-PLA nanoparticles following oral administration. Colloid Surface B, 18:315-23.
42. Tozaki H, Komoike J, Tada C, et al. 1997. Chitosan capsules for colo-specific drug delivery: improvement of insulin absorption from the rat colon. J Pharm Sci, 86:1016-21.
43. Wissing SA, Kayser O, Muller RH. 2004. Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Deliv Rev, 56:1257-72.
44. Yamamoto A, Taniguchi T, Rikyuu K, et al. 1994. Effects of various protease inhibitors on the intestinal absorption and degradation of insulin in rats. Pharm Res, 11: 1496-500.
45. Zhang N, Ping Q, Huang G, et al. 2006. Lectin-modified solid lipid nanoparticles as carriers for oral administration of insulin. Int J Pharm, 327:153-9.
46. Ziv E, Bendayan M. 2000. Intestinal absorption of peptides through the enterocytes. Microsc Res Tech, 49:346-52.
47. Ziv E, Lior O, Kidron M. 1987. Absorption of protein via the intestinal wall. A quantitative model. Biochem Pharmacol, 36:1035-9.